Literature DB >> 12874388

Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.

Melanie Rolli1, Emilia Fransvea, Jan Pilch, Alan Saven, Brunhilde Felding-Habermann.   

Abstract

Expression of adhesion receptor integrin alphavbeta3 in an activated functional form strongly promotes metastasis in human breast cancer cells. Here, we report that alphavbeta3 cooperates with matrix metalloproteinase type 9 (MMP-9) in breast cancer cell migration. This cooperation is regulated by the activation state of the integrin. Expression of activated alphavbeta3 in metastatic variants of MDA-MB 435 human breast cancer cells and primary metastatic cells from breast cancer patients strongly enhanced migration toward vitronectin and fibrinogen. This enhancement was mediated by a soluble factor produced by breast cancer cells expressing activated alphavbeta3. When transferred, this factor also up-regulated alphavbeta3-dependent migration of breast cancer cells that express the nonactivated integrin. The factor was identified as metalloproteinase MMP-9. Whereas all tested breast cancer cell variants produced latent MMP-9, only those with activated alphavbeta3 produced the mature form of this metalloproteinase. Recombinant mature MMP-9, but not latent MMP-9 or either form of MMP-2, enhanced alphavbeta3-dependent breast cancer cell migration. The migratory response was inhibited by tissue inhibitors of metalloproteinase or when MMP-9 was depleted from the inducing supernatants. The results indicate a causal relationship between the expression of activated integrin alphavbeta3 and production of enzymatically active MMP-9 in metastatic breast cancer cells. These molecules cooperate to enhance breast cancer cell migration toward specific matrix proteins, and this may contribute to the strongly enhanced metastatic capacity of breast cancer cells that express activated alphavbeta3.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874388      PMCID: PMC170944          DOI: 10.1073/pnas.1633689100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Networks and crosstalk: integrin signalling spreads.

Authors:  Martin A Schwartz; Mark H Ginsberg
Journal:  Nat Cell Biol       Date:  2002-04       Impact factor: 28.824

Review 2.  Proteases in invasion: matrix metalloproteinases.

Authors:  W G Stetler-Stevenson; A E Yu
Journal:  Semin Cancer Biol       Date:  2001-04       Impact factor: 15.707

3.  Rac recruits high-affinity integrin alphavbeta3 to lamellipodia in endothelial cell migration.

Authors:  W B Kiosses; S J Shattil; N Pampori; M A Schwartz
Journal:  Nat Cell Biol       Date:  2001-03       Impact factor: 28.824

4.  An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase.

Authors:  Boris I Ratnikov; Dmitri V Rozanov; Tanya I Postnova; Peter G Baciu; Heying Zhang; Richard G DiScipio; Galina G Chestukhina; Jeffrey W Smith; Elena I Deryugina; Alex Y Strongin
Journal:  J Biol Chem       Date:  2001-12-10       Impact factor: 5.157

5.  Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase.

Authors:  Elena I Deryugina; Boris I Ratnikov; Tanya I Postnova; Dmitri V Rozanov; Alex Y Strongin
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

6.  Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma.

Authors:  R E Seftor; E A Seftor; N Koshikawa; P S Meltzer; L M Gardner; M Bilban; W G Stetler-Stevenson; V Quaranta; M J Hendrix
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

7.  NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.

Authors:  O Dormond; A Foletti; C Paroz; C Rüegg
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

8.  Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions.

Authors:  Jan Pilch; Rolf Habermann; Brunhilde Felding-Habermann
Journal:  J Biol Chem       Date:  2002-04-04       Impact factor: 5.157

9.  Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts.

Authors:  Roberta Faccio; Maria Grano; Silvia Colucci; Antonello Villa; Gianluigi Giannelli; Vito Quaranta; Alberta Zallone
Journal:  J Cell Sci       Date:  2002-07-15       Impact factor: 5.285

Review 10.  Insights into integrin-ligand binding and activation from the first crystal structure.

Authors:  Martin J Humphries
Journal:  Arthritis Res       Date:  2002-05-09
View more
  110 in total

Review 1.  Fistulising Crohn's disease: MMPs gone awry.

Authors:  D Schuppan; T Freitag
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 2.  Integrins in mammary gland development and differentiation of mammary epithelium.

Authors:  Ilaria Taddei; Marisa M Faraldo; Jérôme Teulière; Marie-Ange Deugnier; Jean Paul Thiery; Marina A Glukhova
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

Review 3.  Casting a net on dendritic spines: the extracellular matrix and its receptors.

Authors:  Lorraine E Dansie; Iryna M Ethell
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

4.  In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.

Authors:  Lucie Sancey; Valérie Ardisson; Laurent M Riou; Mitra Ahmadi; Danièle Marti-Batlle; Didier Boturyn; Pascal Dumy; Daniel Fagret; Catherine Ghezzi; Jean-Philippe Vuillez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-04       Impact factor: 9.236

5.  Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.

Authors:  Diana Matias; Joana Balça-Silva; Luiz Gustavo Dubois; Bruno Pontes; Valéria Pereira Ferrer; Luciane Rosário; Anália do Carmo; Juliana Echevarria-Lima; Ana Bela Sarmento-Ribeiro; Maria Celeste Lopes; Vivaldo Moura-Neto
Journal:  Cell Oncol (Dordr)       Date:  2017-04-11       Impact factor: 6.730

6.  Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2010-11-01       Impact factor: 5.285

7.  Multiple catalytic aldolase antibodies suitable for chemical programming.

Authors:  Rajib Kumar Goswami; Zheng-Zheng Huang; Jane S Forsyth; Brunhilde Felding-Habermann; Subhash C Sinha
Journal:  Bioorg Med Chem Lett       Date:  2009-04-18       Impact factor: 2.823

8.  Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production.

Authors:  Elisabetta Buommino; Adone Baroni; Nunzia Canozo; Marcella Petrazzuolo; Rosario Nicoletti; Antonio Vozza; Maria Antonietta Tufano
Journal:  Invest New Drugs       Date:  2008-10-28       Impact factor: 3.850

9.  Cyclin D1b Splice Variant Promotes αvβ3-mediated EMT Induced by LPS in Breast Cancer Cells.

Authors:  Bao-Ping Luo; Jing Luo; Yi-Bing Hu; Xiao-Wei Yao; Feng-Hua Wu
Journal:  Curr Med Sci       Date:  2018-06-22

Review 10.  Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner.

Authors:  Thomas Dittmar; Christoph Heyder; Eva Gloria-Maercker; Wolfgang Hatzmann; Kurt S Zänker
Journal:  Clin Exp Metastasis       Date:  2007-09-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.